Log In/Sign Up
Your email has been sent.
DaVita Dialysis & Richmond Nephrology 671 Hioaks Rd 14,647 SF 100% Leased Office Building Richmond, VA 23225 $8,780,747 CAD ($599.49 CAD/SF) 6% Cap Rate

Investment Highlights
- Proximity to Chippenham Hospital
- Long-Term Leases with 2.75% Annual Rent Escalations (Avg.)
- Integrated Referral Advantage
- Established Tenant Operating History
Executive Summary
Peranich Huffman Net Lease Group is pleased to offer the exclusive opportunity to acquire DaVita Dialysis & Richmond Nephrology Associates, a 14,647-square-foot dual-tenant medical property located at 671 Hioaks Road, Richmond, VA. The property is 100% occupied on 1.15 acres and reflects a 6.00% capitalization rate on net operating income of $388,471. Originally constructed in 1991 and renovated in 2016, the facility serves dialysis and nephrology patients in the Richmond market and features a weighted-average lease term remaining of approximately 11.2 years.
Property Facts
Sale Type
Investment
Property Type
Office
Property Subtype
Medical
Building Size
14,647 SF
Building Class
C
Year Built
1991
Price
$8,780,747 CAD
Price Per SF
$599.49 CAD
Cap Rate
6%
NOI
$526,845 CAD
Percent Leased
100%
Tenancy
Multiple
Building Height
2 Stories
Typical Floor Size
7,324 SF
Building FAR
0.29
Lot Size
1.16 AC
Zoning
R-3 - Commercial
1 1
Property Taxes
| Parcel Number | C005-0776-033 | Improvements Assessment | $2,795,445 CAD |
| Land Assessment | $550,349 CAD | Total Assessment | $3,345,794 CAD |
Property Taxes
Parcel Number
C005-0776-033
Land Assessment
$550,349 CAD
Improvements Assessment
$2,795,445 CAD
Total Assessment
$3,345,794 CAD
1 of 2
Videos
Matterport 3D Exterior
Matterport 3D Tour
Photos
Street View
Street
Map
1 of 1
Presented by
DaVita Dialysis & Richmond Nephrology | 671 Hioaks Rd
Already a member? Log In
Hmm, there seems to have been an error sending your message. Please try again.
Thanks! Your message was sent.
Your message has been sent!
Activate your LoopNet account now to track properties, get real-time alerts, save time on future inquiries, and more.
